HOME >> MEDICINE >> NEWS
UC researcher utilizes historical control group for new osteoporatic fracture analysis

Cincinnati, Ohio, June 19, 2002 In a new analysis of a study funded by Procter & Gamble Pharmaceuticals, Nelson Watts, MD, professor of medicine at the University of Cincinnati (UC) and director of the UC Bone Health and Osteoporosis Center, has applied an innovative new method for analyzing fracture efficacy for an osteoporosis therapy in a study that was conducted without a placebo control group. The original study was intended to compare two different dose forms of Actonel (risedronate sodium tablets), a new 35 mg a new once a week dose to the 5 mg daily dose, for the treatment and prevention of osteoporosis in postmenopausal women, and thus did not have a placebo control group. Dr. Watts constructed a historical placebo control group from patients in previous Actonel trials to evaluate fracture reduction efficacy of Actonel 35 mg once-a-week. The use of a historical placebo control helps address ethical concerns associated with giving a placebo to clinical trial participants when proven treatments are available in a therapeutic area.

The data, which was presented at the 84th Annual Meeting of the Endocrine Society in San Francisco, represents the first published analysis of fracture reduction using historical placebo control with an osteoporosis therapy. The novel analysis suggests that once a week treatment with Actonel reduced the risk of new vertebral fractures at one year by 77 percent in postmenopausal women. As previously reported, once-a-week treatment with Actonel 35 mg has been found to increase bone mineral density similarly to Actonel 5 mg at one year. Actonel 35 mg once a week was recently approved by the FDA for the treatment and prevention of osteoporosis in postmenopausal women.

"Historical controls have been used in therapeutic areas such as oncology and surgery; however, we are only beginning to make use of this approach in osteoporosis studies," said Dr. Watts. Using statistical methodology, Dr. Watts and his colleagu
'"/>

Contact: Brian Devenny
bdevenny@hillandknowlton.com
212-885-0315
Hill and Knowlton
21-Jun-2002


Page: 1 2

Related medicine news :

1. U of M researcher says Viagra may cause permanent vision loss in some men
2. Indiana University researchers closer to helping hearing-impaired using stem cells
3. Protein that helps skin cancer spread identified by Stanford researchers
4. US life expectancy about to decline, researchers say
5. Gene for age-related macular degeneration discovered by Yale researchers
6. Dartmouth researchers find where musical memories are stored in the brain
7. Columbia researchers receive $3 million to combat genetic killer of infants & toddlers
8. US cancer researchers launch first American-Israeli cancer conference
9. Mayo Clinic researcher calls for improved newborn screening
10. Hard choices: Pitt researcher presents findings on when to accept organ transplants
11. Brain-scanning technologies need standards, according to Stanford researcher

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology:
Cached News: